arrow
F

Finn Gustafsson

copenhagen university hospital
H-index:81
Citation Count:3.8万
Views:0

Biography

No content for now.

Education

No content for now.

Work Experience

No content for now.

Honors & Awards

No content for now.

Angiogenic biomarker concentrations and their relation to coronary atherosclerosis in women with a history of preeclampsia: Findings from the CPH-PRECIOUS study

子痫前期病史女性中血管生成生物标志物浓度及其与冠状动脉动脉粥样硬化的关系:CPH-PRECIOUS研究的结果

2026-09-140
OAAI
Dapagliflozin in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: The DAPAH randomized controlled trial

达格列净在肺动脉高压和慢性血栓栓塞性肺动脉高压中的应用:DAPAH随机对照试验

2026-08-310
PRE
Interferon-gamma release assay screening before solid organ transplantation in a low-incidence country: a prospective single-center cohort study

在低流行国家实体器官移植前干扰素-γ释放试验筛查:一项前瞻性单中心队列研究

2026-06-060
OAAI
Amiodarone-related thyroid dysfunction and associated outcomes in patients with heart failure—A nationwide cohort study

胺碘酮相关甲状腺功能异常及其在心力衰竭患者中的相关结局——一项全国性队列研究

2026-05-260
OAAI
Stroke and Bleeding Risk in Cardiac Amyloidosis: A Danish Nationwide Matched Cohort Study

淀粉样变性心脏病的卒中与出血风险:一项丹麦全国性匹配队列研究

2026-05-100
PRE
Survival Outcomes in Middle-aged and Older Patients with Advanced Heart Failure: A Propensity-Matched Analysis of HeartMate 3 LVAD and Heart Transplant Using MOMENTUM 3 and UNOS Registry

中老年晚期心力衰竭患者生存结局:基于MOMENTUM 3和UNOS登记研究的HeartMate 3左心室辅助装置与心脏移植的倾向性匹配分析

2026-05-100
OAAI
Concomitant Tricuspid Valve Surgery During HeartMate 3 LVAD Implantation and Long-Term Outcomes: Insights From the ELEVATE Registry

同期三尖瓣手术在HeartMate 3 LVAD植入术中的应用及长期预后:来自ELEVATE登记研究的研究结果

2026-04-010
PRE
Clinical Application of Guideline-Directed Medical Therapy in TAVR Patients With Heart Failure and Reduced Ejection Fraction

指南指导的药物治疗在合并心力衰竭及射血分数降低的TAVR患者中的临床应用

2026-01-120
PRE
Long-term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trials (Vol 278,pg 106, 2024)
2025-12-010
OAAI
Impact of Atrial Fibrillation, Diabetes Mellitus and Obesity on Outcomes with Aspirin Avoidance and Hemocompatibility with a Left Ventricular Assist Device: An analysis from the ARIES-HM3 Trial

心房颤动、糖尿病和肥胖对停用阿司匹林及左心室辅助装置血液相容性影响的结果:一项来自ARIES-HM3试验的分析

2025-11-260
OAAI
Hemocompatibility Outcomes With Pharmacological Therapy Following LVAD Implantation

LVAD植入术后药物疗法下的血液相容性结局

2025-11-190
OAAI
Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial

左心室辅助装置且接受维生素K拮抗剂治疗的患者停用阿司匹林:随机ARIES-HM3试验中抗凝质量的影响

2025-11-011
OA
Multimodality imaging in advanced heart failure. A clinical consensus statement of the Heart Failure Association of the ESC. Part 1: Multimodality imaging for the evaluation of patients with advanced heart failure

心脏衰竭晚期中的多模态成像。欧洲心脏病学会心力衰竭协会的临床共识声明。第一部分:用于评估心脏衰竭晚期患者的多模态成像。

2025-10-140
PRE
Multimodality imaging in advanced heart failure. A clinical consensus statement of the Heart Failure Association of the ESC. Part 2: Mechanical circulatory support and heart transplantation

心力衰竭的多模态成像。欧洲心脏病学会心力衰竭协会的临床共识声明。第2部分:机械循环支持和心脏移植

2025-10-140
PRE
Worsening versus advanced heart failure: Management and challenges

恶化与进展性心力衰竭:管理与挑战

2025-10-040
OAAI
SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI

SGLT2抑制剂在心力衰竭的预防和治疗中的应用:HFA和HFAI的科学声明

2025-09-190
OAAI
Management of aortic stenosis and chronic heart failure: A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC

主动脉瓣狭窄和慢性心力衰竭的管理:欧洲心力衰竭协会(HFA)和欧洲经皮心血管介入协会(EAPCI)的ESC临床共识声明

2025-09-150
PRE
Identifying and overcoming barriers to referral in advanced heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC

识别和克服心衰患者转诊中的障碍。欧洲心脏病学会(ESC)心力衰竭协会(HFA)的科学声明

2025-08-170
OAAI
A multicentre, randomized, double-blind, active and placebo-controlled study of pecavaptan, a dual V1a/V2 vasopressin receptor antagonist, in patients with acute heart failure: The AVANTI trial

一项关于pecavaptan(一种双重V1a/V2血管加压素受体拮抗剂)在急性心力衰竭患者中进行的多中心、随机、双盲、活性药物和安慰剂对照研究:AVANTI试验

2025-08-110
PRE
Absence of coronary artery disease in patients under going coronar y imaging and association with amyloidosis: A Danish nationwide study

冠状动脉疾病在行冠状动脉成像患者中的缺失及其与淀粉样变性的关联:一项丹麦全国性研究

2025-05-060
OAAI